WEREWOLF THERAPEUTICS, INC. Contract with Customer, Receivable, after Allowance for Credit Loss
WEREWOLF THERAPEUTICS, INC. (HOWL) had Contract with Customer, Receivable, after Allowance for Credit Loss of $5.00 million as of 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Notes
us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss · last filed 2023-11-14
- 2023-09-30: Contract with Customer, Receivable, after Allowance for Credit Loss $5.00M.
- 2022-12-31: Contract with Customer, Receivable, after Allowance for Credit Loss $2.80M.
| Period end | Contract with Customer, Receivable, after Allowance for Credit Loss |
|---|---|
| 2023-09-30 | $5.00M 10-Q · filed 2023-11-14 |
| 2022-12-31 | $2.80M 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |